Bone Biologics (BBLG) Equity Average (2016 - 2017)
Bone Biologics has reported Equity Average over the past 2 years, most recently at -$9.3 million for Q4 2017.
- Quarterly Equity Average fell 21.21% to -$9.3 million in Q4 2017 from the year-ago period, while the trailing twelve-month figure was -$9.3 million through Dec 2017, down 21.21% year-over-year, with the annual reading at -$8.4 million for FY2017, 33.42% down from the prior year.
- Equity Average was -$9.3 million for Q4 2017 at Bone Biologics, up from -$9.9 million in the prior quarter.
- Over five years, Equity Average peaked at -$3.7 million in Q1 2016 and troughed at -$9.9 million in Q3 2017.